Cargando…

Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C(22)H(29)FO(5)) intratympanic injection

Serous otitis media (SOM) occurs in children and constitutes one of the most significant causes of hearing loss in young age, posing as an important risk factor for long-term hearing loss. SOM is underdiagnosed, most frequently in infants, or the appointment to the ENT doctor is delayed due to non-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mârțu, Cristian, Cozma, Sebastian, Cobzeanu, Bogdan, Vesa, Doina, Butnaru, Corina, Bularda, Dragoș, Cumpătă, Adeline, Rădulescu, Luminița
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713185/
https://www.ncbi.nlm.nih.gov/pubmed/34970348
http://dx.doi.org/10.3892/etm.2021.11048
_version_ 1784623719691321344
author Mârțu, Cristian
Cozma, Sebastian
Cobzeanu, Bogdan
Vesa, Doina
Butnaru, Corina
Bularda, Dragoș
Cumpătă, Adeline
Rădulescu, Luminița
author_facet Mârțu, Cristian
Cozma, Sebastian
Cobzeanu, Bogdan
Vesa, Doina
Butnaru, Corina
Bularda, Dragoș
Cumpătă, Adeline
Rădulescu, Luminița
author_sort Mârțu, Cristian
collection PubMed
description Serous otitis media (SOM) occurs in children and constitutes one of the most significant causes of hearing loss in young age, posing as an important risk factor for long-term hearing loss. SOM is underdiagnosed, most frequently in infants, or the appointment to the ENT doctor is delayed due to non-acute symptomatology. The aim of the present study was to assess 285 patients with SOM diagnosed within a two-year span. The etiology and pathology of hearing loss in patients with different age groups were examined. The importance of a clinical examination and tympanometry was emphasized as absolutely necessary for a correct diagnosis. Treatment targeted Eustachian Tube permeabilization for satisfactory long-term middle ear aeration. Nasal drops with vasoconstrictor drugs (phenylephrine) and disinfectant (colloidal silver 1%) were commonly used, but some patients also benefitted from dexamethasone intratympanic injection. Patients were evaluated at the end of the treatment and follow-up occurred at one month, one year and three years later.
format Online
Article
Text
id pubmed-8713185
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-87131852021-12-29 Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C(22)H(29)FO(5)) intratympanic injection Mârțu, Cristian Cozma, Sebastian Cobzeanu, Bogdan Vesa, Doina Butnaru, Corina Bularda, Dragoș Cumpătă, Adeline Rădulescu, Luminița Exp Ther Med Articles Serous otitis media (SOM) occurs in children and constitutes one of the most significant causes of hearing loss in young age, posing as an important risk factor for long-term hearing loss. SOM is underdiagnosed, most frequently in infants, or the appointment to the ENT doctor is delayed due to non-acute symptomatology. The aim of the present study was to assess 285 patients with SOM diagnosed within a two-year span. The etiology and pathology of hearing loss in patients with different age groups were examined. The importance of a clinical examination and tympanometry was emphasized as absolutely necessary for a correct diagnosis. Treatment targeted Eustachian Tube permeabilization for satisfactory long-term middle ear aeration. Nasal drops with vasoconstrictor drugs (phenylephrine) and disinfectant (colloidal silver 1%) were commonly used, but some patients also benefitted from dexamethasone intratympanic injection. Patients were evaluated at the end of the treatment and follow-up occurred at one month, one year and three years later. D.A. Spandidos 2022-02 2021-12-07 /pmc/articles/PMC8713185/ /pubmed/34970348 http://dx.doi.org/10.3892/etm.2021.11048 Text en Copyright: © Mârțu et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Mârțu, Cristian
Cozma, Sebastian
Cobzeanu, Bogdan
Vesa, Doina
Butnaru, Corina
Bularda, Dragoș
Cumpătă, Adeline
Rădulescu, Luminița
Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C(22)H(29)FO(5)) intratympanic injection
title Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C(22)H(29)FO(5)) intratympanic injection
title_full Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C(22)H(29)FO(5)) intratympanic injection
title_fullStr Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C(22)H(29)FO(5)) intratympanic injection
title_full_unstemmed Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C(22)H(29)FO(5)) intratympanic injection
title_short Serous otitis media: Clinical and therapeutic considerations, including dexamethasone (C(22)H(29)FO(5)) intratympanic injection
title_sort serous otitis media: clinical and therapeutic considerations, including dexamethasone (c(22)h(29)fo(5)) intratympanic injection
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713185/
https://www.ncbi.nlm.nih.gov/pubmed/34970348
http://dx.doi.org/10.3892/etm.2021.11048
work_keys_str_mv AT martucristian serousotitismediaclinicalandtherapeuticconsiderationsincludingdexamethasonec22h29fo5intratympanicinjection
AT cozmasebastian serousotitismediaclinicalandtherapeuticconsiderationsincludingdexamethasonec22h29fo5intratympanicinjection
AT cobzeanubogdan serousotitismediaclinicalandtherapeuticconsiderationsincludingdexamethasonec22h29fo5intratympanicinjection
AT vesadoina serousotitismediaclinicalandtherapeuticconsiderationsincludingdexamethasonec22h29fo5intratympanicinjection
AT butnarucorina serousotitismediaclinicalandtherapeuticconsiderationsincludingdexamethasonec22h29fo5intratympanicinjection
AT bulardadragos serousotitismediaclinicalandtherapeuticconsiderationsincludingdexamethasonec22h29fo5intratympanicinjection
AT cumpataadeline serousotitismediaclinicalandtherapeuticconsiderationsincludingdexamethasonec22h29fo5intratympanicinjection
AT radulesculuminita serousotitismediaclinicalandtherapeuticconsiderationsincludingdexamethasonec22h29fo5intratympanicinjection